Stock Analiz

JNJ vs NVS stock comparison

Johnson & Johnson vs. Novartis · data as of November 13, 2026

Johnson & Johnson (JNJ) has a market value of about $687.9B, Novartis (NVS) about $306.3B. Over their latest twelve months Johnson & Johnson had revenue of $99.3B and Novartis $57.4B.

On our five checks Johnson & Johnson scores higher: 2.6 out of 5 (average) against 2.0 (weak).

By area, the stronger company is Johnson & Johnson on financial health; Johnson & Johnson on shareholder returns.

Novartis is cheaper on earnings (P/E 30.7 vs. 43.4), while Johnson & Johnson grew revenue faster over five years (2.7% vs. 2.3% a year).

Johnson & Johnson leads on 8 of the compared lines and Novartis on 14.

Side by side

JNJNVS
Size and price
Market cap$687.9B$306.3B
Share price$285.75$160.50
Score
Overall score (of 5)2.62.0
Value00
Future growth00
Track record44
Financial health43
Shareholder returns53
Valuation
P/E (TTM)43.430.7
Forward P/E25.117.0
Price / free cash flow33.421.9
Price / sales6.95.3
EV / EBITDA26.714.4
PEG2.912.02
DCF value vs. price−39%−9%
Business
Revenue$99.3B$57.4B
Net income$16.1B$10.0B
Free cash flow$20.6B$14.0B
Net margin16.2%17.5%
Gross margin (5-yr avg.)69.1%76.4%
ROIC (5-yr avg.)16.6%14.1%
Growth
Revenue growth (1 yr)6.0%8.4%
Revenue growth (5 yrs, per year)2.7%2.3%
EPS growth (5 yrs, per year)14.9%15.2%
Balance sheet and payouts
Net cash (cash minus debt)-$27.4B-$39.3B
Dividend yield1.88%2.95%
Shareholder yield2.8%6.0%
Analysts
Upside to average target−2%−2%
Consensus ratingBuyHold

Highlighted = the better figure on that line. Revenue, net income and free cash flow: JNJ TTM to September 27, 2026, NVS TTM to September 30, 2026. Not investment advice.

Frequently asked questions

Which is the better stock, Johnson & Johnson or Novartis?

We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Johnson & Johnson scores 2.6 out of 5 and Novartis 2.0; the table shows where each one is stronger.

Is Johnson & Johnson cheaper than Novartis?

On trailing earnings, Novartis trades at a P/E of 30.7 and Johnson & Johnson at 43.4, so Novartis is cheaper by this measure. A lower P/E can also reflect slower expected growth.

Which grows faster, Johnson & Johnson or Novartis?

Over five years Johnson & Johnson grew revenue about 2.7% a year and Novartis about 2.3% a year.

Which pays a higher dividend?

Johnson & Johnson yields 1.88% and Novartis 2.95%.

Full Johnson & Johnson analysis → Full Novartis analysis →

More comparisons

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.